Evidence map›Paper›PMID 30967495›Full record

ArticleBioscience reports2019

LSINCT5 predicts unfavorable prognosis and exerts oncogenic function in osteosarcoma.

Weidong He, Ming Lu, Dongbo Xiao

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. LSINCT5: a pivotal oncogenic long non-coding RNA in cancers.Functional & integrative genomics · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Weidong HeDepartment of Joint Surgery, The First People's Hospital of Lianyungang, Lianyungang 222002, Jiangsu, China.
Ming LuDepartment of Orthopedics, Medical School of Chinese PLA, Beijing 100853, China.
Dongbo XiaoDepartment of Orthopedics, Ankang Central Hospital, Ankang 725000, Shaanxi, China xiaodongbosa@126.com.ORCID 0000-0003-3002-6191
Ankang City Central Hospital · CNChinese PLA General Hospital · CNThe First People’s Hospital of Lianyungang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dysregulated expression of LSINCT5 (long stress-induced non-coding transcript 5) has been found in various human tumors, and was generally related to cancer progression and unfavorable prognosis. Although the role of LSINCT5 in osteosarcoma was reported not long ago, the sample size of that study was limited. Our study presented more evidence about the clinical significance and biological function of LSINCT5 in osteosarcoma. In our results, we found LSINCT5 expression was increased in osteosarcoma tissue samples and cell lines, and high LSINCT5 expression was associated with advanced Enneking stage, large tumor size, high histological grade and present distant metastasis. Meanwhile, we observed high LSINCT5 expression was correlated with worse overall survival, and high LSINCT5 expression could be an independent poor predictor for overall survival in osteosarcoma cases. Moreover, we found inhibition of LSINCT5 expression suppressed cell proliferation, migration and invasion

Indexed as

OncogenesCell Line, TumorDisease-Free SurvivalFemaleHumansMaleNeoplasm MetastasisOsteonecrosisOsteosarcomaRNA, Long NoncodingRNA, NeoplasmSurvival RateRNA, Long NoncodingRNA, Neoplasmbiomarkerlarge intervening non-coding RNALSINCT5osteosarcoma

Identifiers

PMID30967495
PMCPMC6500890
OpenAlexW2940090649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.